제품 수집
제품 세부정보
Source
Anti-SARS-CoV-2 Spike RBD Antibody, Mouse IgG1 (9A6A11) (XBB.1.5/Omicron Specific) is isolated from a Spike RBD infected mouse and is recombinantly produced in Hybridoma.
Antibody Type
Hybridoma Monoclonal
Clone
9A6A11
Isotype
Mouse IgG1, Kappa
Host Species
Mouse
Immunogen
Recombinant SARS-CoV-2 Spike RBD Protein (XBB.1.5/Omicron) erived from human 293 cells
Specificity
This product is a specific antibody specifically reacts with SARS-CoV-2 Spike RBD Protein, His Tag (XBB/Omicron). No cross-reactivity is detected with Spike RBD of WT (Cat. No. SPD-C52H3), Alpha (Cat. No. SPD-C52Hn), Beta (Cat. No. SPD-C52Hp), Gamma (Cat. No. SPD-C52Hr), Delta (Cat. No. SPD-C52Hh), B.1.1.529/Omicron (Cat. No. SPD-C522e), BA.2/Omicron (Cat. No. SPD-C522g), BA.3/Omicron, BA.4&5Omicron (Cat. No. SPD-C522r), BA.2.12.1/Omicron, BA.2.75/Omicron (Cat. No. SPD-C522t), BF.7&BA.4.6/Omicron (Cat. No. SPD-C522y), BQ.1.1/Omicron (Cat. No. SPD-C5240). 9A6A11 inhibits the binding of SARS-CoV-2 Spike proteins to ACE2.
Application
ApplicationRecommended Use / PerformanceELISA0.2-2 μg/mLPurification
Protein A purified.
Concentration
Please refer to the Certificate of Analysis (CoA).
Form
Lyophilized
Formulation
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
Shipping
Lyophilized product is shipped at ambient temperature.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Notices
Product Specific Notices: For research use only.
ACRO Quality Management System
고객님도 확인한 상품
데이터 표시
Bioactivity-ELISA
Immobilized SARS-CoV-2 Spike RBD Protein, His Tag (XBB.1.5/Omicron) (MALS verified) (Cat. No. SPD-C5242) and SARS-CoV-2 Spike RBD Protein, His Tag (XBB/Omicron) (MALS verified) (Cat. No. SPD-C5241) can bind Anti-SARS-CoV-2 Spike RBD Antibody, Mouse IgG1 (9A6A11) (XBB.1.5/Omicron Specific) (Cat. No. SPD-Y168) with a linear range of 0.195-12.5ng/mL. The antibody does not bind Spike RBD of WT (Cat. No. SPD-C52H3), Alpha (Cat. No. SPD-C52Hn), Beta (Cat. No. SPD-C52Hp), Gamma (Cat. No. SPD-C52Hr), Delta (Cat. No. SPD-C52Hh), B.1.1.529/Omicron (Cat. No. SPD-C522e), BA.2/Omicron (Cat. No. SPD-C522g), BA.3/Omicron, BA.4&5Omicron (Cat. No. SPD-C522r), BA.2.12.1/Omicron, BA.2.75/Omicron (Cat. No. SPD-C522t), BF.7&BA.4.6/Omicron (Cat. No. SPD-C522y) and BQ.1.1/Omicron (Cat. No. SPD-C5240) (QC tested).
Protocol
사용자 리뷰 댓글 남기기
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
배경 소개
프론티어 진행
연락하기
전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
신약 후보물질 라이선싱
